

Animal testing policy

Statement S2016002 – V2.1

Introduction

As a family-owned business for several generations, MANE has been committed to respecting its environment for over 150 years. The signing of the United Nations Global Compact charter in 2003 paved the way for strategies aimed at developing alternatives to animal testing.

At MANE, the protection of animal welfare and the environment is not just a priority - it is a cornerstone of our identity. This unwavering commitment is reflected in our strict policy of not conducting animal tests on our flavor or fragrance compositions. Furthermore, no animal tests are conducted or commissioned for our manufactured ingredients, except where specifically required by national or regional regulations.

Our proactive stance extends beyond compliance. **We are determined pioneers in the search for alternative methods**, investing in cutting-edge research and collaboration to drive the future of ethical testing. Since 2007, MANE has been a shareholder in ImmunoSearch, a research company dedicated to the development of in vitro toxicological testing.

Since 2008, we have incorporated alternative methods for skin irritation screening in our laboratories, using the EpiSkin® model.

In addition, we collaborate and have partnered with and invested in R&D companies specializing in non-animal testing methodologies, including QSAR modeling (in silico approaches) like:

- **KREATIS** (collaboration since 2019, partner since 2021).
- **Blue Frog Scientific** (collaboration since 2022).

This policy builds on our long-standing history of action, reaffirming MANE's relentless dedication to combining scientific innovation, environmental responsibility, and ethical principles in every aspect of our work.

Adherence to the 3Rs Principles

MANE applies the 3Rs principles in its operations:

- **Replacement:** Promote validated alternative methods to avoid the use of animals (e.g., *in silico* models, cell cultures).
- **Reduction:** Minimize required tests by leveraging available data and methodologies such as read across.
- **Refinement:** Mitigate the impact on animals when testing is mandatory.



Conditions for Animal Testing

MANE strives to avoid animal testing. When such tests are mandated by regulations, MANE ensures they are conducted only when strictly necessary to meet regulatory requirements and when no alternative is available:

1. Tests are outsourced to contract laboratories, which provide GLP-compliant reports.
2. These laboratories use the most relevant methodologies to minimize their impact.
3. MANE collaborates with partners holding appropriate certifications.

Partnerships for Innovation

Scientific innovation is essential to advance the field of animal-free testing. MANE actively supports:

- **Immunosearch:** Developing alternative models based on human cells:
 - MANE contributes to the development of SENSis.
 - MANE supports new project on carcinogenesis (chronic toxicity).
- **KREATIS:** *In silico* approaches providing substitute solutions to traditional tests.
 - MANE contributes to the development of a new *in silico* New Approach Methodology (NAM) to discriminate classified/not-classified chemical substances for acute oral toxicity (iSafeRat®).
 - MANE supported the development of the prediction sensitization endpoint in iSafeRat® tool.

These collaborations reinforce our contribution to the adoption of New Approach Methodologies (NAMs) by regulatory authorities and professional associations.

To complement our strategy, we are engaged in the activities of associations and collaborative projects in this field (e.g., EPAA, ICCS).

Continuous Commitment

MANE will continue to invest in:

- Partnerships focusing on alternative methodologies.
- Training and monitoring in this continuously evolving field.

Our long-term goal is to fully replace animal testing wherever feasible.

This commitment reflects our dedication to combining scientific rigor and ethical principles in the development of our products.

Eric ANGELINI
VP Global Regulatory Affairs & Product Safety
13 January 2025